Ignite Creation Date:
2025-12-24 @ 11:28 PM
Ignite Modification Date:
2025-12-25 @ 9:15 PM
Study NCT ID:
NCT03952156
Status:
TERMINATED
Last Update Posted:
2023-08-29
First Post:
2019-05-09
Is Possible Gene Therapy:
True
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Gene Therapy Clinical Study in Adult PKU
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D010661', 'term': 'Phenylketonurias'}], 'ancestors': [{'id': 'D020739', 'term': 'Brain Diseases, Metabolic, Inborn'}, {'id': 'D001928', 'term': 'Brain Diseases, Metabolic'}, {'id': 'D001927', 'term': 'Brain Diseases'}, {'id': 'D002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D000592', 'term': 'Amino Acid Metabolism, Inborn Errors'}, {'id': 'D008661', 'term': 'Metabolism, Inborn Errors'}, {'id': 'D030342', 'term': 'Genetic Diseases, Inborn'}, {'id': 'D009358', 'term': 'Congenital, Hereditary, and Neonatal Diseases and Abnormalities'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1', 'PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SEQUENTIAL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 10}}, 'statusModule': {'whyStopped': 'Homology Medicines has discontinued the development of this program.', 'overallStatus': 'TERMINATED', 'startDateStruct': {'date': '2019-06-10', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2023-08', 'dispFirstSubmitDate': '2023-02-02', 'completionDateStruct': {'date': '2023-08-01', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2023-08-24', 'studyFirstSubmitDate': '2019-05-09', 'dispFirstSubmitQcDate': '2023-02-02', 'studyFirstSubmitQcDate': '2019-05-14', 'dispFirstPostDateStruct': {'date': '2023-02-13', 'type': 'ACTUAL'}, 'lastUpdatePostDateStruct': {'date': '2023-08-29', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2019-05-16', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2023-01-10', 'type': 'ACTUAL'}}, 'outcomesModule': {'otherOutcomes': [{'measure': 'Phenylketonuria Quality of Life Questionnaire (PKU-QOL)', 'timeFrame': 'Baseline to Week 52', 'description': 'Change in PKU-QOL'}], 'primaryOutcomes': [{'measure': 'Incidence and severity of treatment-emergent adverse events (TEAEs) (Dose Escalation Phase)', 'timeFrame': 'Baseline to Week 52', 'description': 'Subjects with at least one TEAE or serious TEAE'}, {'measure': 'Change from baseline in clinical laboratory values (Dose Escalation Phase)', 'timeFrame': 'Baseline to Week 52', 'description': 'Change in serum chemistry values including liver function tests, hematology, and urinalysis'}, {'measure': 'Change from baseline in 12-lead electrocardiograms (ECGs), vital signs, physical examinations (Dose Escalation Phase)', 'timeFrame': 'Baseline to Week 52', 'description': 'Subjects change from baseline in 12-lead electrocardiograms (ECGs), vital signs, physical examinations'}, {'measure': 'Incidence of sustained plasma Phe concentration of ≤360 μmol/L at 28 weeks post dose (Dose Escalation Phase)', 'timeFrame': 'Week 28', 'description': 'Subjects achieving a sustained plasma Phe concentration ≤360 μmol/L at 28 weeks post dose'}, {'measure': 'Change from baseline in Plasma Phe Concentration (Dose Escalation Phase)', 'timeFrame': 'Weeks 24-28', 'description': 'Change from baseline in plasma Phe concentration during Weeks 24-28'}, {'measure': 'Change from baseline in mean Plasma Phe Concentration (Dose Expansion Phase)', 'timeFrame': 'Weeks 24-28', 'description': 'Change from baseline in mean plasma Phe concentration during Weeks 24-28'}], 'secondaryOutcomes': [{'measure': 'Incidence of plasma Phe concentration thresholds up to Week 28 post administration of HMI-102 (Dose Expansion Phase)', 'timeFrame': 'Baseline to Week 28', 'description': 'Subjects achieving plasma Phe concentration thresholds up to Week 28 post administration of HMI-102'}, {'measure': 'Incidence of plasma Phe concentration thresholds up to Week 52 post administration of HMI-102 (Dose Expansion Phase)', 'timeFrame': 'Baseline to Week 52', 'description': 'Subjects achieving plasma Phe concentration thresholds up to Week 52 post administration of HMI-102'}, {'measure': 'Change from baseline in total protein intake at Week 52 post-administration of HMI-102 (Dose Expansion Phase)', 'timeFrame': 'Week 52', 'description': 'Subject Achieving a change from baseline in total protein intake at Week 52 post-administration of HMI-102'}, {'measure': 'Incidence and severity of treatment-emergent adverse events (TEAEs) (Dose Expansion Phase)', 'timeFrame': 'Baseline to Week 52', 'description': 'Subjects with at least one TEAE or serious TEAE'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['PKU', 'Phenylketonuria', 'PAH Deficiency', 'Hyperphenylalaninemia', 'Phenylalanine', 'Adeno Associated Virus', 'AAVHSC15'], 'conditions': ['Phenylketonurias', 'PAH Deficiency']}, 'descriptionModule': {'briefSummary': 'This is a Phase 1/2, open-label, randomized, concurrently-controlled, dose escalation study to evaluate the safety and efficacy of HMI-102 in adult PKU subjects with PAH deficiency. Participants will receive a single administration of HMI-102 and will be followed for safety and efficacy for 1 year.', 'detailedDescription': 'Part 1 of this study will evaluate the safety and efficacy of HMI-102 gene therapy in adult subjects with PKU due to PAH deficiency. Subjects will receive a single dose of HMI-102 administered intravenously. Up to 3 dose levels of HMI-102 may be investigated in this study. At a given dose level, a minimum of 2 subjects will be enrolled and dosed. Dosing of the first two subjects will be staggered. Following evaluation of data from the first 2 subjects in a cohort, a decision can be made to either escalate to the next dose level or expand the cohort at the selected dose level. Additional doses may be added by HMI to investigate intermediate or higher doses.\n\nIn Part 2 dose expansion, evaluation of up to 2 dose levels is planned. Subjects will be randomized to receive HMI-102 or a concurrent delayed treatment control arm. Subjects in the delayed treatment control will be eligible to receive HMI-102 after 28 weeks.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT'], 'maximumAge': '55 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Key Inclusion Criteria:\n\n* Adults 18-55 years of age at the time of informed consent\n* Diagnosis of phenylketonuria (PKU) due to PAH deficiency\n* Two plasma Phe values with a concentration of ≥ 600 μmol/L drawn at least 72 hours apart during the screening period and at least one historical value ≥ 600 μmol/L in the preceding 24 months.\n* Subject has the ability and willingness to maintain their baseline diet, whether Phe-restricted or unrestricted for the duration of the trial, unless otherwise directed\n\nKey Exclusion Criteria:\n\n* Subjects with PKU that is not due to PAH deficiency\n* Presence of anti-AAVHSC15 neutralizing antibodies\n* ALT \\> ULN and AST \\> ULN\n* Alkaline phosphatase \\> ULN.\n* Total bilirubin \\> ULN, direct bilirubin \\> ULN\n* Serum creatinine \\>1.5x ULN\n* International normalized ratio (INR) \\> 1.2\n* Hematology values outside of the normal range (hemoglobin \\<11.0 g/dL for males or \\<10.0 g/dL for females; white blood cells (WBC) \\<3,000/μL; absolute neutrophils \\<1500/μL; platelets \\<100,000/μL)\n* Hemoglobin A1c \\>6.5% or fasting glucose \\>126 mg/dL\n* Any clinically significant abnormal laboratory result at screening, in the opinion of the Investigator\n* Contraindication to corticosteroid use or conditions that could worsen in the presence of corticosteroids, as assessed and determined by the investigator\n* Previously received gene therapy for the treatment of any condition.'}, 'identificationModule': {'nctId': 'NCT03952156', 'acronym': 'pheNIX', 'briefTitle': 'Gene Therapy Clinical Study in Adult PKU', 'organization': {'class': 'INDUSTRY', 'fullName': 'Homology Medicines, Inc'}, 'officialTitle': 'A Phase 1/2 Open-Label, Randomized, Concurrently-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of HMI-102 in Adult PKU Subjects With PAH Deficiency', 'orgStudyIdInfo': {'id': 'HMI-102-101'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Cohort 1', 'description': 'Dose Level 1 of HMI-102 delivered intravenously one time', 'interventionNames': ['Genetic: HMI-102']}, {'type': 'EXPERIMENTAL', 'label': 'Cohort 2', 'description': 'Dose Level 2 of HMI-102 delivered intravenously one time', 'interventionNames': ['Genetic: HMI-102']}, {'type': 'EXPERIMENTAL', 'label': 'Cohort 3', 'description': 'Dose Level 3 of HMI-102 delivered intravenously one time', 'interventionNames': ['Genetic: HMI-102']}, {'type': 'EXPERIMENTAL', 'label': 'Delayed Treatment Control', 'description': 'Delayed Treatment Control Arm', 'interventionNames': ['Genetic: HMI-102']}, {'type': 'EXPERIMENTAL', 'label': 'Expansion Phase First Dose level', 'description': 'Expansion Phase First Dose Level of HMI-102 delivered intravenously one time', 'interventionNames': ['Genetic: HMI-102']}, {'type': 'EXPERIMENTAL', 'label': 'Expansion Phase Second Dose level', 'description': 'Expansion Phase Second Dose Level of HMI-102 delivered intravenously one time', 'interventionNames': ['Genetic: HMI-102']}], 'interventions': [{'name': 'HMI-102', 'type': 'GENETIC', 'description': 'HMI-102 is an AAVHSC15 vector containing a functional copy of the human PAH gene', 'armGroupLabels': ['Cohort 1', 'Cohort 2', 'Cohort 3', 'Expansion Phase First Dose level', 'Expansion Phase Second Dose level']}, {'name': 'HMI-102', 'type': 'GENETIC', 'description': 'Control subjects will generally have the same assessments as treated subjects.\n\nControl subjects will undergo pre-baseline procedures to confirm that they are eligible to receive treatment with HMI-102. Once eligible control subjects are dosed with HMI-102, they will initiate the same post-dose procedures as subjects who received HMI-102.', 'armGroupLabels': ['Delayed Treatment Control']}]}, 'contactsLocationsModule': {'locations': [{'zip': '90027', 'city': 'Los Angeles', 'state': 'California', 'country': 'United States', 'facility': 'Kaiser Permanente Los Angeles Medical Center', 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}, {'zip': '92868', 'city': 'Orange', 'state': 'California', 'country': 'United States', 'facility': "Children's Hospital of Orange County", 'geoPoint': {'lat': 33.78779, 'lon': -117.85311}}, {'zip': '33606', 'city': 'Tampa', 'state': 'Florida', 'country': 'United States', 'facility': 'University of South Florida', 'geoPoint': {'lat': 27.94752, 'lon': -82.45843}}, {'zip': '30322', 'city': 'Atlanta', 'state': 'Georgia', 'country': 'United States', 'facility': 'Emory University Hospital', 'geoPoint': {'lat': 33.749, 'lon': -84.38798}}, {'zip': '60611', 'city': 'Chicago', 'state': 'Illinois', 'country': 'United States', 'facility': "Lurie Children's Hospital of Chicago", 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}, {'zip': '02115', 'city': 'Boston', 'state': 'Massachusetts', 'country': 'United States', 'facility': "Boston Children's Hospital", 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'zip': '10029', 'city': 'New York', 'state': 'New York', 'country': 'United States', 'facility': 'Icahn School of Medicine at Mount Sinai', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '27599', 'city': 'Chapel Hill', 'state': 'North Carolina', 'country': 'United States', 'facility': 'The University of North Carolina At Chapel Hill', 'geoPoint': {'lat': 35.9132, 'lon': -79.05584}}, {'zip': '43205', 'city': 'Columbus', 'state': 'Ohio', 'country': 'United States', 'facility': "Nationwide Children's Hospital", 'geoPoint': {'lat': 39.96118, 'lon': -82.99879}}, {'zip': '19104', 'city': 'Philadelphia', 'state': 'Pennsylvania', 'country': 'United States', 'facility': "Children's Hospital of Philadelphia", 'geoPoint': {'lat': 39.95238, 'lon': -75.16362}}, {'zip': '15224', 'city': 'Pittsburgh', 'state': 'Pennsylvania', 'country': 'United States', 'facility': "UPMC Children's Hospital of Pittsburgh", 'geoPoint': {'lat': 40.44062, 'lon': -79.99589}}, {'zip': '75235', 'city': 'Dallas', 'state': 'Texas', 'country': 'United States', 'facility': 'University of Texas Southwestern Medical Center', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'zip': '84108', 'city': 'Salt Lake City', 'state': 'Utah', 'country': 'United States', 'facility': 'University of Utah', 'geoPoint': {'lat': 40.76078, 'lon': -111.89105}}], 'overallOfficials': [{'name': 'Olaf A Bodamer, M.D.', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': "Boston Children's Hospital"}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Homology Medicines, Inc', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}